1. Australian drug evaluation committee (1988) Guidelines for the production of monoclonals intended for therapeutic use, National Biological Standards Laboratory, Common-wealth Department of Health.
2. Bartal AH, Feit C, Erlandson R and Hirshaut Y (1982) The presence of virus particles in clones secreting monoclonal antibodies. New Med. 306(23): 1423.
3. Bartal AH and Hirshaut Y (1987) Retrovirus and hybridoma formation, bystanders or active participants? In: Bartal and Hirshaut (eds) Methods of Hybridoma formation (pp. 41?61) Humana Press, USA.
4. Builder SE, Ogez JR, Van Reis R, Paoni NF, Arathoon R and Lubiniecki AS (1989) Process development and regulatory control of tissue type plasminogen activator. In: Spier RE, Griffiths JB, Crooy P and Stephenne J (eds) Advances in animal cell biology and technology (pp. 452?464) Butterworths, Guildford.
5. Carthew P (1986) Is rodent virus contamination of monoclonal antibody preparations for use in human therapy a hazard? J. Gen. Virol. 67: 963?974.